BibTex RIS Cite

Karotid Endarterektomi geçiren hastalarda kontrolsüz diyabetin statin kullanan ve kullanmayan hastalarda LDL seviyelerine etkisi

Year 2016, Volume: 26 Issue: 2, 50 - 52, 01.06.2016

Abstract

Amaç: Çalışmanın amacı Karotid endarterektomi geçiren hastalarda kontrolsüz diyabetes mellitusun DM uzun süreli statin kullanan ve kullanmayan hastalarda Düşük Yoğunluklu Lipoprotein LDL seviyelerine etkisini araştırmaktı.Gereç ve yöntem: Ateroskleroz nedeniyle karotid endarterektomi geçiren 40 hastanın ameliyat öncesi LDL seviyeleri retrospektif olarak analiz edildi. Tüm hastalar en az 1 yıldır statin kullanıyordu. HbA1C seviyelerinin % 6,4’den fazla olması kontrolsüz DM kriteri kabul edildi D+ . Diğer hastalar diyabet olmayan gruplara alındı D- . Grup 1: D+ statin kullanan n=9 , grup 2: D- statin kullanan n=10 , grup 3: D+ statin kullanmayan n=8 , grup 4: D- statin kullanmayan n=13 hastalardan oluştu. İstatistiksel değerlendirme için Kruskal-Wallis ve Mann-Whitney testleri kullanıldı. p

References

  • IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract 2015;109:461-5.
  • Whayne TF Jr. Atherosclerosis: current status of prevention and treatment. Int J Angiol 2011;20:213-22.
  • Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin 2014;32:439-55.
  • Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 2005;150:859-70.
  • Maki KC, Dicklin MR, Baum SJ. Statins and diabetes. Cardiol Clin 2015;33:233-43.
  • Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Prote- ction Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
  • Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
  • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowe- ring of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
  • Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matt- hews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
  • Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpu- salo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
  • Eeg-Olofsson K, Gudbjörnsdottir S, Eliasson B, Zethelius B, Cederholm J; NDR. The triglycerides-to-HDL-cholesterol ra- tio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Di- abetes Register (NDR). Diabetes Res Clin Pract 2014;106:136- 44.
  • Kei A, Rizos EC, Elisaf M. Statin use in prediabetic patients: rationale and results to date. Ther Adv Chronic Dis 2015;6:246- 51.
  • Naples M, Fredico LM, Xu E, Nelken J, Adeli K. Effect of ro- suvastatin on insülin sensivity in an animal model of insülin resistance: evidence of statin-induced hepatic insülin sensitiza- tion. Atherosclerosis 2008;198:94-103.
Year 2016, Volume: 26 Issue: 2, 50 - 52, 01.06.2016

Abstract

Introduction: This study aims to assess the effects of uncontrolled diabetes mellitus DM on LDL levels of atherosclerotic patients on long term statins and patients not on statins.Material and Methods: LDL levels of 40 patients undergoing carotid endarterectomy due to atherosclerosis were retrospectively analyzed. All statin users were on statins for >1yr. Patients with HbA1C levels of >6.4% were considered as uncontrolled DM D+ . All other patients were non diabetics D- . Group1: D+, statin user n=9 , group 2: D- statin user n=10 , group 3: D+ non statin user n=8 , and group 4: D- non statin user n=13 . LDL levels are given as mg/dl, Kruskal-Wallis and Mann-Whitney tests were used for statistics. p0.05 . Conclusions: Results of this study suggest that atherosclerotic patients with uncontrolled diabetes who are either on or off statin therapy have higher LDL results compared to non-diabetic atherosclerotic patients. Further multicenter studies with higher number of patients with proven atherosclerosis are needed

References

  • IDF Diabetes Atlas Group. Update of mortality attributable to diabetes for the IDF Diabetes Atlas: Estimates for the year 2013. Diabetes Res Clin Pract 2015;109:461-5.
  • Whayne TF Jr. Atherosclerosis: current status of prevention and treatment. Int J Angiol 2011;20:213-22.
  • Aronson D, Edelman ER. Coronary artery disease and diabetes mellitus. Cardiol Clin 2014;32:439-55.
  • Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance. Am Heart J 2005;150:859-70.
  • Maki KC, Dicklin MR, Baum SJ. Statins and diabetes. Cardiol Clin 2015;33:233-43.
  • Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Prote- ction Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
  • Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
  • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowe- ring of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81.
  • Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matt- hews DR, Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
  • Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpu- salo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.
  • Eeg-Olofsson K, Gudbjörnsdottir S, Eliasson B, Zethelius B, Cederholm J; NDR. The triglycerides-to-HDL-cholesterol ra- tio and cardiovascular disease risk in obese patients with type 2 diabetes: an observational study from the Swedish National Di- abetes Register (NDR). Diabetes Res Clin Pract 2014;106:136- 44.
  • Kei A, Rizos EC, Elisaf M. Statin use in prediabetic patients: rationale and results to date. Ther Adv Chronic Dis 2015;6:246- 51.
  • Naples M, Fredico LM, Xu E, Nelken J, Adeli K. Effect of ro- suvastatin on insülin sensivity in an animal model of insülin resistance: evidence of statin-induced hepatic insülin sensitiza- tion. Atherosclerosis 2008;198:94-103.
There are 13 citations in total.

Details

Primary Language Turkish
Journal Section Original Article
Authors

Mehmet Alkılıç Öç This is me

İpek Duman This is me

Hüsamettin Vatansev This is me

Murat Şimşek This is me

Oğuzhan Arun This is me

Bahar Öç This is me

Ateş Duman This is me

Publication Date June 1, 2016
Published in Issue Year 2016 Volume: 26 Issue: 2

Cite

Vancouver Öç MA, Duman İ, Vatansev H, Şimşek M, Arun O, Öç B, Duman A. Karotid Endarterektomi geçiren hastalarda kontrolsüz diyabetin statin kullanan ve kullanmayan hastalarda LDL seviyelerine etkisi. Genel Tıp Derg. 2016;26(2):50-2.